Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navitoclax in Relapsed or Refractory Lymphoid Malignancies
NCT00406809Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Nov 2006
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of navitoclax in lymphoid malignancy, chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), follicular lymphoma (FL), mantle cell lymphoma (MCL), sponsored by AbbVie Inc.. Started Nov 2006; status: completed.
02
Drugs
navitoclax
03
Conditions
lymphoid malignancychronic lymphocytic leukemia (CLL)non-Hodgkin lymphoma (NHL)follicular lymphoma (FL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT00406809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00406809.